STOCKS TELEGRAPH

Tag: MannKind Corporation

  • Will MannKind Corporation (MNKD) Stock Rise in 2025? What Investors Need to Know

    Will MannKind Corporation (MNKD) Stock Rise in 2025? What Investors Need to Know

    MannKind Corporation (NASDAQ: MNKD) is a biotechnology and pharmaceutical company specializing in inhaled therapeutics for diabetes and pulmonary diseases. Best known for Afrezza®, an inhaled insulin, MannKind has positioned itself as a key innovator in diabetes treatment, offering an alternative to traditional injectable insulin. The company also focuses on its Technosphere® drug delivery platform, which has the potential to expand into other therapeutic areas, making it a compelling biotech stock to watch.

    In recent years, MNKD stock has attracted significant investor interest, driven by growing demand for diabetes treatments, new product developments, and expanding partnerships. However, the stock has experienced volatility, reflecting both the high-risk, high-reward nature of biotech investments and broader market conditions affecting the pharmaceutical sector.

    With analyst ratings, market demand, and upcoming catalysts influencing investor sentiment, the key question remains: Will MNKD stock rise in 2025, or should investors remain cautious? This article will explore MNKD stock’s performance, growth drivers, risks, and expert predictions, providing insights for investors considering this biotech stock in their portfolio.

    MNKD Stock Performance & Financial Overview

    Recent Stock Trends & Price Movement

    MannKind Corporation (MNKD) has experienced significant price fluctuations over the past year, reflecting both market sentiment and broader biotech sector movements. Over the last 52 weeks, MNKD stock has traded between $ 7.63 and $3.57, showcasing its volatility in response to earnings reports, drug pipeline updates, and macroeconomic factors.

    Investor interest in MNKD stock has been fueled by strong revenue growth, FDA approvals, and expanded partnerships. However, periodic sell-offs have occurred due to market corrections, competitive pressures, and concerns over profitability. Despite this, the stock has shown resilience, with analysts closely monitoring its trajectory in 2025 and beyond.

    Revenue, Earnings & Profit Margins

    MannKind’s financial performance has demonstrated steady revenue growth, driven by Afrezza sales, licensing agreements, and new product developments. In its most recent quarterly earnings report, the company reported:

    • Revenue: $70.079 million, up from 51.23 M YoY.
    • Net Income: $11.55 million, reflecting improved operational efficiency.
    • EPS Growth (TTM): $ 0.07 per share, signaling enhanced profitability.

    The company’s cash flow position has improved, with manageable debt levels supporting continued R&D investments. However, profitability remains a concern, as biotech companies often require extensive capital for clinical trials and regulatory approvals.

    Key Financial Metrics

    • Market Cap: $1.56 billion.
    • P/E Ratio: 70.63, compared to industry industry median of -2.04.
    • Earnings Per Share (EPS): $0.042, reflecting recent growth trends.
    • Debt-to-Equity Ratio: -1.14, indicating financial leverage.

    Comparing MNKD stock to peers like Dexcom (DXCM) and Insulet (PODD), MannKind offers a niche advantage in the inhaled insulin market but faces challenges in scaling profitability. Investors should consider these key financials when evaluating MNKD’s potential upside.

    Growth Drivers: Why MNKD Stock Could Rise in 2025

    A. Expanding Product Portfolio & Revenue Streams

    MannKind Corporation (NASDAQ: MNKD) has positioned itself as a leader in inhaled drug delivery technology, with its flagship product Afrezza®, an FDA-approved inhaled insulin. As demand for alternative diabetes treatments increases, Afrezza sales continue to show steady growth, with the potential for global expansion into new markets.

    Beyond insulin, MannKind’s Technosphere® drug delivery platform presents an opportunity for diversification into pulmonary and respiratory therapies. The company has been actively working on new drug formulations, leveraging Technosphere technology to enhance bioavailability and patient compliance.

    Additionally, MNKD is exploring new revenue streams through licensing agreements and pharmaceutical partnerships. Investors should closely watch pipeline drug developments, which could significantly boost revenue and profitability in the coming years.

    1. Increased Demand for Diabetes & Pulmonary Treatments

    The global diabetes epidemic continues to drive demand for innovative treatment solutions, particularly non-invasive alternatives like Afrezza. With millions of people diagnosed with diabetes and respiratory diseases each year, the market potential for MNKD’s products remains strong.

    • Afrezza® offers advantages over traditional insulin injections, providing faster absorption and greater patient convenience.
    • Rising cases of pulmonary diseases, including COPD and lung infections, present an opportunity for Technosphere-based inhalable therapies.
    • Regulatory approvals or expanded indications for Afrezza® and other MNKD products could unlock new growth opportunities.

    With rising healthcare awareness and a shift toward patient-friendly drug delivery methods, MNKD is well-positioned to capitalize on long-term demand trends in the biopharmaceutical market.

    C. Strategic Partnerships & Licensing Agreements

    MannKind’s collaborations with major pharmaceutical firms have been instrumental in driving innovation and expanding its market reach. Key strategic partnerships include:

    • United Therapeutics (UTHR): A multi-year agreement to develop inhalable treatments for pulmonary hypertension using MNKD’s Technosphere platform.
    • Receptor Life Sciences: Partnering to explore inhalable cannabinoid-based therapies for neurological disorders.
    • Potential licensing opportunities with global biotech companies could bring in additional revenue through milestone payments and royalties.

    Latest Analyst Ratings on MNKD Stock

    MannKind Corporation (MNKD) has recently received positive analyst coverage, reflecting growing confidence in the stock’s potential. On December 20, 2024, Wells Fargo’s Tiago Fauth initiated coverage on MNKD stock with an Overweight rating and a price target of $9.00, signaling optimism about the company’s growth prospects. Just a day earlier, Gregory Renza from RBC Capital upgraded MNKD from Sector Perform to Outperform, raising the price target from $7.00 to $10.00, reinforcing a bullish stance.

    Earlier in August 2024, Oppenheimer’s Steven Lichtman maintained an Outperform rating, adjusting the price target upward from $10.00 to $12.00, suggesting strong upside potential. Meanwhile, Brandon Folkes of Rodman & Renshaw initiated coverage in June 2024 with a Buy rating and an $8.00 price target, adding to the stock’s growing appeal among institutional investors. In May 2024, Cantor Fitzgerald’s Olivia Brayer reiterated her Overweight rating, maintaining a $6.50 price target, showing long-term confidence in the stock despite market volatility.

    The consensus among analysts remains bullish, with multiple price target upgrades and strong buy recommendations, indicating that MNKD stock could see continued momentum heading into 2025. However, investors should keep an eye on regulatory updates, product developments, and market trends to assess MNKD’s true growth potential.

    Bearish Case: Risks That Could Impact MNKD Stock in 2025

    A. Market Volatility & Economic Risks

    Like many biotech stocks, MannKind Corporation (NASDAQ: MNKD) remains vulnerable to macroeconomic factors such as interest rate hikes, inflation, and overall economic downturns. The biotech sector is often considered high-risk, high-reward, meaning that when market sentiment shifts toward risk aversion, investors tend to pull funds from speculative biotech stocks like MNKD.

    Additionally, the performance of biotech stocks in recent years has been mixed, with many small-cap biotech firms struggling to maintain stock momentum amid economic uncertainty. If market conditions deteriorate in 2025, MNKD could face higher volatility, impacting its stock price performance.

    B. Competitive Pressure in the Biotech Industry

    MannKind operates in an industry dominated by pharmaceutical giants, particularly in the diabetes treatment market. Companies like Novo Nordisk (NVO) and Eli Lilly (LLY) hold significant market share with their well-established insulin therapies.

    Afrezza¬Æ, MannKind’s inhalable insulin, offers an alternative to traditional insulin injections, but gaining widespread adoption has been a challenge.

    Endocrinologists and healthcare providers may be reluctant to shift away from conventional treatments, creating barriers to Afrezza’s market penetration.

    Novo Nordisk’s Ozempic¬Æ and Eli Lilly’s Mounjaro¬Æ have gained tremendous traction in the diabetes and weight-loss market, making it harder for MNKD to capture significant market share.

    MannKind needs to differentiate its technology, expand its product portfolio, and prove that Afrezza® can be a mainstream diabetes treatment to compete effectively in the long term.

    C. Regulatory & FDA Approval Challenges

    FDA approvals and regulatory processes play a crucial role in the biotech industry, and MannKind is no exception. While Afrezza is already FDA-approved, any future product developments or pipeline drugs using Technosphere® technology must undergo rigorous regulatory scrutiny.

    Potential challenges include:

    Clinical trial setbacks, Which could delay new product launches.

    Regulatory rejections or additional study requirements, which impact MNKD’s growth prospects.

    Extended FDA review periods, can slow down commercialization timelines.

    A delay in obtaining FDA approvals for new indications or partnership drugs could stall revenue growth and affect investor confidence in MNKD’s long-term potential.

    D. Valuation Concerns & Stock Dilution Risks

    From a valuation standpoint, MNKD stock has been volatile, raising concerns about whether it is fairly valued or overvalued compared to its earnings and revenue growth. Key valuation risks include:

    MNKD’s price-to-earnings (P/E), price-to-sales (P/S), and book value multiples are higher than some competitors, raising concerns that the stock may be overvalued.

    Stock dilution risks: As a small-cap biotech company, MNKD may need to raise capital for R&D, marketing, and expansion efforts. This could lead to secondary stock offerings, potentially diluting existing shareholders’ value.

    Short interest and speculative trading have impacted MNKD stock before, meaning sudden downward movements could occur if sentiment shifts negatively.

    Market Sentiment & Investor Interest in MNKD Stock

    A. Institutional Ownership & Major Investors in MNKD Stock

    Institutional investors hold a significant stake in MannKind Corporation (NASDAQ: MNKD), with approximately 56.86% of shares owned by financial institutions. Among the top corporate investors, D. E. SHAW & CO., INC. leads with a 2.7 million shareholding, valued at approximately $12.24 million, representing a 1% ownership stake in MNKD.

    Additionally, JUMP FINANCIAL, LLC maintains a smaller position, holding 130.65K shares, with a total valuation of $591.85K, which accounts for 0.05% of the company’s outstanding shares. The strong institutional backing reflects growing confidence among hedge funds and large investment firms, signaling potential long-term stability and market credibility for MNKD stock.

    B. Market Sentiment & Investor Sentiment Trends for MNKD Stock

    Investor sentiment surrounding MannKind Corporation (NASDAQ: MNKD) has experienced notable fluctuations over the past six months, reflecting shifting market sentiment based on social media discussions, news coverage, and analyst opinions.

    • One-Week Sentiment Score: MNKD’s weekly sentiment score currently stands at 15, driven by 35 social media mentions, 1 news article, and 1 opinion article. This marks a significant rebound of 20.71 points from -5.71 the previous week, with the sentiment score fluctuating between -7.41 and 15 over the last seven days.
    • One-Month Sentiment Score: Over the past month, sentiment has slightly weakened, with MNKD’s one-month sentiment score sitting at 13.83, based on 158 social media posts, 1 news article, and 1 opinion piece. This represents a drop of 26.85 points from the previous 40.68 score. The sentiment score has ranged between -2.94 to 41.18 during this period, indicating increased investor caution.
    • Six-Month Sentiment Score: Looking at a broader timeframe, MNKD’s six-month sentiment score currently stands at 26.73, based on 815 social media posts, 13 news articles, and 6 opinion pieces. This marks a decline of 19.6 points from 46.33 recorded six months ago. The sentiment score has fluctuated between 22.78 and 46.33, suggesting periods of optimism followed by cautious pullbacks.

    While short-term sentiment has seen a recent rebound, the one-month and six-month trends indicate declining enthusiasm among investors. This suggests that MNKD stock has been experiencing market uncertainty, possibly due to broader biotech sector volatility, regulatory concerns, or financial performance expectations.

    MNKD Stock Price Prediction: Short-Term Projections

    MannKind Corporation (NASDAQ: MNKD) is expected to experience moderate upward momentum based on recent stock price predictions. The forecast suggests that MNKD stock could trade within the range of $5.42 to $5.84 over the next few trading sessions, with a slight uptrend in expected price levels.

    MNKD Stock Price Forecast (Upcoming Sessions)

    • February 26, 2025
      • Lower Bound: $5.55
      • Predicted Price: $5.69
      • Upper Bound: $5.84
    • February 27, 2025
      • Lower Bound: $5.52
      • Predicted Price: $5.66
      • Upper Bound: $5.82
    • February 28, 2025
      • Lower Bound: $5.50
      • Predicted Price: $5.64
      • Upper Bound: $5.80
    • March 3, 2025
      • Lower Bound: $5.46
      • Predicted Price: $5.61
      • Upper Bound: $5.75
    • March 4, 2025
      • Lower Bound: $5.42
      • Predicted Price: $5.57
      • Upper Bound: $5.73

    Support & Resistance Levels: The stock appears to have strong support around $5.42, while the upper price projections approach the $5.84 resistance level.

    Investor Sentiment: Positive sentiment, along with market catalysts such as earnings reports or strategic developments, could drive MNKD’s stock price beyond current resistance levels.

    The Verdict: Should You Buy, Hold, or Sell MNKD Stock in 2025?

    MannKind Corporation (NASDAQ: MNKD) presents a mixed investment case heading into 2025. The stock has shown strong growth potential, particularly through expanding Afrezza® sales, licensing agreements, and a promising Technosphere® platform. However, market risks, competition, and regulatory uncertainties remain key concerns that could impact its long-term trajectory.

    Bullish Case for MNKD Stock

    • Expanding revenue streams from Afrezza® and Tyvaso DPI.
    • Growing demand for diabetes and pulmonary treatments, with potential global expansion.
    • Increasing analyst price targets and institutional investor interest.
    • Strong partnerships with pharmaceutical companies, particularly United Therapeutics, ensuring stable revenue streams.

    Bearish Case for MNKD Stock

    • Regulatory uncertainties—delays or FDA rejections could slow growth.
    • Competitive pressure from industry leaders like Novo Nordisk and Eli Lilly.
    • Stock dilution risks, with potential secondary offerings to raise capital.
    • Market volatility and macroeconomic risks that could affect biotech stocks.

    Final Verdict

    • Long-term investors may find MNKD stock an attractive growth play, given its pipeline potential and established product base. However, they should be prepared for volatility and regulatory hurdles.
    • Short-term traders should monitor upcoming FDA approvals, earnings reports, and market sentiment, as these could drive price swings.
    • Risk-averse investors may prefer to wait for further clarity on clinical trials and market expansion before making a decision.

    Overall, MNKD is a “Hold” for most investors, a “Buy” for risk-tolerant growth seekers, and a “Sell” only for those unwilling to withstand biotech sector volatility.

  • What Explains 10% Rise In MNKD Stock In Premarket Session Today?

    What Explains 10% Rise In MNKD Stock In Premarket Session Today?

    At the last check today, MannKind Corporation (MNKD) had reached $4.48, good for an increase of 9.27% in premarket session. The MannKind stock price dropped -0.73% to $4.10 at the end of the last trading session. MNKD stock price ranged between $4.08 and $4.18. MNKD stock surged on approval of its drug by authorities.

    In what way did the achievement succeed?

    MannKind specializes in developing and commercializing inhaled therapeutic products for patients with endocrine and orphan lung diseases. Afrezza Inhalation Powder is currently being sold by MNKD. As the only mealtime insulin available in the United States that is inhaled and acts very quickly, Afrezza is MNKD’s first FDA-approved product. All pharmacies in the United States offer the drug on prescription.

    The US Food and Drug Administration (FDA) today accepted the New Drug Application (NDA) for priority review submitted by MannKind and United Therapeutics Corporation (Nasdaq: UTHR). Tyvaso DPI (inhaled treprostinil) from MNKD has been given a priority review status for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseases (PH-ILD).

    MNKD’s Technosphere technology is being used to formulate the second compound to be reviewed by the FDA, which should be completed in October 2021. Also, FDA officials have said they haven’t found any issues with the review process at the moment.

    MNKD moving forward:

    This important step will allow MannKind (MNKD) to produce the next Technosphere product more conveniently for thousands of PAH and PH-ILD patients. As of September 2018, MNKD and United Therapeutics have signed an exclusive licensing and collaboration agreement for Tyvaso DPI.

    MNKD’s Tyvaso DPI manufacturing facility will be inspected by the FDA before the FDA approves the Tyvaso NDA. In the third quarter of 2021, FDA and MNKD plan to complete the inspections.

  • What changed for these 49 stocks in Pre-Market Session?

    What changed for these 49 stocks in Pre-Market Session?

    Fuel Tech Inc. (FTEK) stock plunged -8.8% to $1.14 in the pre-market trading after the technology company offered advanced engineering solutions for the optimization of combustion, pollution control, and water treatment systems in utility and industrial applications, financial results for the third quarter were officially published. The most recent rating by H.C. Wainwright, on March 13, 2020, is at a Neutral.

    Equillium Inc. (NASDAQ: EQ) shares are trading down -4.17% at $4.83 at the time of writing after on November 11, the company announced quarterly results for the third quarter of 2020. The company’s 52-week range was noted as $2.20 to $27.05. Analysts have a consensus price target of $24.

    Immuron Limited (IMRN) tumbled over -4.17% at $8.05 in pre-market trading today. US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine.

    Infinity Pharmaceuticals Inc. (INFI), a Biotechnology company, dropped about -6.62% at $1.41 in pre-market trading Thursday following an earnings surprise of -6.67 percent was revealed by the company. It was anticipated a quarter ago that this drugmaker would report a loss of $0.20 per share when it actually posted a $0.16 loss, providing a 20 percent surprise.
    .

    Tellurian Inc. (TELL) stock moved down -5.6 percent to $1.18 in the pre-market trading following the company finished the third quarter of 2020, with cash and cash equivalents of roughly $77.9 million and current borrowings of about $80.8 million. The balance sheet of Tellurian accounted for about $293.3 million in total assets.

    Co-Diagnostics Inc. (CODX) gained over 5.19% at $13.99 in pre-market trading Thursday 12 November 2020. Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction.

    Abeona Therapeutics Inc. (ABEO) is down more than -3.85% at $1.25 in pre-market hours Thursday 12 November 2020 after a front-runner in gene and cell therapy, revealed quarterly results and business updates. The stock had jumped over 13.04% to $1.30 in the last trading session.

    Before the trading started on 12 November 2020, MannKind Corporation (MNKD) is down -3.57% to reach $2.7. It has been trading in a 52-week range of $0.80 to $2.52.

    RAVE Restaurant Group Inc. (RAVE) stock plunged -11.84% to $0.67 in the pre-market trading. The most recent rating by ROTH Capital, on May 12, 2016, is at a Neutral.

    Dada Nexus Limited (NASDAQ: DADA) shares are trading up 5.08% at $32.7 at the time of writing. The company’s 52-week range was noted as $14.60 to $37.38. Analysts have a consensus price target of $36.

    FuelCell Energy Inc. (FCEL) tumbled over -1.49% at $2.65 in pre-market trading today.

    Zoom Video Communications Inc. (ZM), a Telecom Services company, rose about 3.38% at $427.3 in pre-market trading Thursday.

    Canaan Inc. (CAN) stock moved up 3.05 percent to $2.7 in the pre-market trading.

    Muscle Maker Inc. (GRIL) lost over -9.6% at $1.79 in pre-market trading Thursday 12 November 2020.

    Moderna Inc. (MRNA) is up more than 5.03% at $86.59 in pre-market hours Thursday 12 November 2020. The stock had jumped over 8.40% to $82.44 in the last trading session. Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273).

    Before the trading started on 12 November 2020, Coty Inc. (COTY) is down -3.89% to reach $4.45 after the company topped analysts’ outlook and surged as much as 22.2% on Nov 6 following its first-quarter fiscal 2021 results. It has been trading in a 52-week range of $2.65 to $13.01.

    Pinduoduo Inc. (PDD) stock soared 17.53% to $131.0 in the pre-market trading following an innovative and emerging tech firm and one of the top Chinese e-commerce players, revealed its unaudited financial results for the third quarter ended September 30, 2020. The most recent rating by Goldman, on November 03, 2020, is a Buy.

    Sea Limited (NYSE: SE) shares are trading up 3.48% at $175.01 at the time of writing following the news recently that pharmaceutical companies are closing on their COVID-19 vaccine candidates. The company’s 52-week range was noted as $30.50 to $187.75. Analysts have a consensus price target of $164.

    GrowGeneration Corp. (GRWG) grew over 7.26% at $22.46 in pre-market trading today after GrowGeneration reported record third-quarter 2020 Financial Results.

    Blink Charging Co. (BLNK), a Specialty Retail company, rose about 5.09% at $10.73 in pre-market trading Thursday.

    LightInTheBox Holding Co. Ltd. (LITB) stock moved up 3.31 percent to $2.5 in the pre-market trading.

    Bionano Genomics Inc. (BNGO) gained over 14.13% at $0.639 in pre-market trading Thursday 12 November 2020. Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients.

    Vroom Inc. (VRM) is down more than -9.88% at $36.77 in pre-market hours Thursday 12 November 2020 following Vroom reported third Quarter 2020 results. The stock had jumped over 6.56% to $40.80 in the last trading session.

    Before the trading started on 12 November 2020, Turkcell Iletisim Hizmetleri A.S. (TKC) is up 3.16% to reach $5.23. It has been trading in a 52-week range of $4.36 to $6.36.

    Himax Technologies Inc. (HIMX) stock soared 12.2% to $4.6 in the pre-market trading after the prediction of Revenue to surge by approx. 10% consecutively and Gross Margin to get close to 29%. The most recent rating by Credit Suisse, on April 01, 2020, is at an Outperform.

    Qualigen Therapeutics Inc. (NASDAQ: QLGN) shares are trading down -10.03% at $3.23 at the time of writing. The company’s 52-week range was noted as $3.29 to $21.50.

    NovaBay Pharmaceuticals Inc. (NBY) grew over 8.82% at $0.67 in pre-market trading today.

    IMAC Holdings Inc. (IMAC), a Medical Care Facilities company, rose about 146.1% at $2.05 in pre-market trading Thursday. IMAC Holdings, Inc. Expands Missouri Footprint with Acquisition of Lockwood Chiropractic in Webster Groves.

    Sino-Global Shipping America Ltd. (SINO) stock moved up 62.18 percent to $3.13 in the pre-market trading.

    InVivo Therapeutics Holdings Corp. (NVIV) lost over -3.21% at $0.555 in pre-market trading Thursday 12 November 2020.

    Castor Maritime Inc. (CTRM) is up more than 18.5% at $0.1595 in pre-market hours Thursday 12 November 2020 after the company posted fiscal Results for the Three Months and Nine Months Ended September 30, 2020. The stock had jumped over 4.95% to $0.13 in the last trading session.

    Before the trading started on 12 November 2020, Just Energy Group Inc. (JE) is down -13.28% to reach $5.29 as a retail energy provider specializing in electricity and natural gas commodities, revealed its quarterly results for the fiscal year 2021. It has been trading in a 52-week range of $4.27 to $93.72.

    OraSure Technologies Inc. (OSUR) stock soared 4.55% to $14.02 in pre-market trading after the company recently topped its 3rd quarter fiscal earnings predictions. The most recent rating by Evercore ISI, on August 21, 2020, is at an Outperform.

    Riot Blockchain Inc. (NASDAQ: RIOT) shares are trading up 4.17% at $3.75 at the time of writing after the news that Bitcoin might take off again after a big gap. The company’s 52-week range was noted as $0.51 to $4.58.

    NortonLifeLock Inc. (NLOK) tumbled over -7.02% at $18.68 in pre-market trading today despite the earnings beat in the recent week.

    NIO Limited (NIO), an Auto Manufacturers company, rose about 3.41% at $44.55 in pre-market trading Thursday after the analyst’s prediction that NIO can be the main player in the Electric Vehicle market.

    JD.com Inc. (JD) stock moved up 5.38 percent to $87.3 in the pre-market trading following the news that JD.com was the largest US seller in China on Singles day.

    Kandi Technologies Group Inc. (KNDI) gained over 8.84% at $6.77 in pre-market trading Thursday 12 November 2020 despite its disappointing sales results in the financial 3rd quarter of this year.

    ICL Group Ltd (ICL) is up more than 3.11% at $3.98 in pre-market hours Thursday 12 November 2020 as the company topped analysts’ outlook on every front. The stock had jumped over 3.21% to $3.86 in the last trading session.

    Before the trading started on 12 November 2020, Uxin Limited (UXIN) is down -3.81% to reach $1.01 after the news that the company’s proprietary rating system has been introduced that assesses and determines the quality of a used vehicle, offers greater precision to make the decision-making process simpler for consumers and enhances the overall consumer experience. The stock has been trading in a 52-week range of $0.72 to $3.30.

    Baozun Inc. (BZUN) stock soared 3.07% to $40.57 in pre-market trading after the news that the stock still carries a great potential for investors. The most recent rating by Credit Suisse, on June 03, 2020, is at an Outperform.

    XpresSpa Group Inc. (NASDAQ: XSPA) shares are trading up 4.47% at $1.87 at the time of writing after the news that the firm to offer Business Update and will reveal Third Quarter 2020 Financial Results on November 16, 2020. The company’s 52-week range was noted as $0.15 to $8.82.

    KE Holdings Inc. (BEKE) grew over 3.48% at $72.02 in pre-market trading today after the news that the company will announce its quarterly report on November 16, 2020.

    Revolve Group Inc. (RVLV), an Internet Retail company, dropped about -8.96% at $20.43 in pre-market trading Thursday after the company Announced Third Quarter 2020 Financial Results with topping all analysts predictions.
    .

    American Tower Corporation (REIT) (AMT) stock moved up 2.75 percent to $245.0 in the pre-market trading after the reports that the company took over InSite Wireless Group for USD 3.5 billion.

    BIO-key International Inc. (BKYI) gained over 16.2% at $0.52 in pre-market trading Thursday 12 November 2020.

    Liminal BioSciences Inc. (LMNL) is up more than 11.19% at $4.57 in pre-market hours Thursday 12 November 2020 after the report that the firm will reschedule its announcement of quarterly results and conference call. The stock had jumped over 2.49% to $4.11 in the last trading session.

    Before the trading started on 12 November 2020, GoHealth Inc. (GOCO) is down -4.5% to reach $12.73. It has been trading in a 52-week range of $10.02 to $26.25.

    XPeng Inc. (XPEV) stock soared 10.53% to $37.06 in pre-market trading after the company unveiled upbeat quarterly results. The most recent rating by Citigroup, on November 04, 2020, is a Buy.

  • Here’s Why You Should Hold These 15 Biotech Stocks

    Here’s Why You Should Hold These 15 Biotech Stocks

    The biotechnology industry is considered to be an attractive industry for investors as the investors are always looking for safe and secure investments. This industry is a good option for investors as it is a strong and profitable industry. Companies in the biotechnology industry are continuously striving and exploring treatment for rare diseases. This industry has a significant contribution to the well-being of society. The biotechnology industry is constantly experiencing tech improvements and new scientific discoveries.

    Technology has always been at the heart of the biotechnology industry. New technological advancements are helpful for the biotechnology industry. This industry is anticipated to show a higher growth rate over the period of the next seven years. Globally, it is predicted that this industry will generate massive revenue in the coming years and it will also provide investment opportunities to investors who want to invest in the research and development of this industry.

    The following are the leading companies in the biotechnology industry. Let check how these companies are providing the best services to their clients:

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares were trading down -10.49% at $9.30 at the time of writing on Friday. Sorrento Therapeutics Inc. (NASDAQ: SRNE) share price went from a low point around $1.45 to briefly over $19.39 in the past 52 weeks, though shares have since pulled back to $9.30. SRNE market cap has remained high, hitting $2.72B at the time of writing, giving it a price-to-sales ratio of more than 70.

    Sorrento Therapeutics Inc. (SRNE) has announced earlier that it has secured the receipt of clearance from a Brazilian regulatory agency to continue with a Phase 2 clinical trial of Abivertinib in mild, moderate, and severe COVID-19 patients. If we look at the recent analyst rating SRNE, H.C. Wainwright reiterated coverage on SRNE shares with a Buy rating.

    EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT)

    EyePoint Pharmaceuticals Inc. (EYPT) last closed at $0.48, in a 52-week range of $0.46 to $2.69. EyePoint Pharmaceuticals Inc. (EYPT) revealed changes to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the covenant associated with the Company’s net product revenue of DEXYCU and YUTIQ for the twelve-month period ending on December 31, 2020.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (VXRT) stock drop by -3.49% to $6.08. The most recent rating by H.C. Wainwright, on August 12, 2020, is at a Buy. The Schall Law Firm disclosed that the class-action lawsuit has been lodged against Vaxart, Inc. (VXRT)  for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) shares headed falling, lower as much as -4.59%. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral. Novan Inc. (NOVN) revealed earlier that the positive in vitro results exhibited the potential efficacy of its NITRICIL™ platform technology as an antiviral against SARS-CoV-2, the virus that causes COVID-19.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 3.42% after gaining more than $0.13 on Friday. Akebia Therapeutics Inc. (AKBA) revealed that it is scheduled to present data from its global Phase 3 programs of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis ) and not on dialysis at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week) on October 22 – 25, 2020.

    Royalty Pharma plc (NASDAQ: RPRX)

    Royalty Pharma plc (RPRX) last closed at $41.81, in a 52-week range of $38.54 to $56.50. Analysts have a consensus price target of $52.67. Royalty Pharma plc (RPRX) disclosed today that it is scheduled to announce its third-quarter 2020 financial results on Wednesday, November 11, 2020, before the U.S. financial markets open.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceuticals Incorporated (VRTX) stock soar by 1.30% to $218.08. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Vertex Pharmaceuticals Incorporated (VRTX) shared an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) Shares headed falling, lower as much as -1.44%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) earlier revealed it has appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.29, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) earlier disclosed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1×1 meetings scheduled through the Bio Partnering system.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) Shares headed falling, lower as much as -2.17%. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier disclosed the initiation of a rolling submission to Health Canada for mRNA-1273. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults.

    Selecta Biosciences Inc. (NASDAQ: SELB)

    Selecta Biosciences Inc. (NASDAQ: SELB) rose 18.01% after gaining more than $0.38 on Friday. Selecta Biosciences Inc. (SELB) has earlier announced an agreement with IGAN Biosciences, Inc. The agreement is the Research License and Option agreement signed to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).

    Immunomedics Inc. (NASDAQ: IMMU)

    Immunomedics Inc. (NASDAQ: IMMU) stock soar by 0.08% to $87.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics Inc. (IMMU) disclosed that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy orphan status for the treatment of adult and pediatric patients with glioblastoma.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) fall -0.75% after losing more than -$0.05 on Friday. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks. It has moved up 102.56% from its 52-weeks low and moved down -65.83% from its 52-weeks high. CLVS market cap has remained high, hitting $532.72 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock drop by -2.95% to $11.85. The most recent rating by Maxim Group, on September 28, 2020, is at a Buy. Inovio Pharmaceuticals Inc. (INO) share price went from a low point around $2.09 to briefly over $33.79 in the past 52 weeks. It has moved up 456.84% from its 52-weeks low and moved down -65.56% from its 52-weeks high. INO market cap has remained high, hitting $2.05 Billion at the time of writing.

    MannKind Corporation (NASDAQ: MNKD)

    MannKind Corporation (NASDAQ: MNKD) last closed at $2.00, in a 52-week range of $0.80 to $2.48. MannKind Corporation (MNKD) has moved up 157.08% from its 52-weeks low and moved down -17.07% from its 52-weeks high. MNKD market cap has remained high, hitting $441.20 Million at the time of writing.